Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 0.75 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an education grant from Novartis Pharmaceuticals Corporation.

Show Me Your Care Plan! Managing Adverse Events Associated with CAR T-Cell Therapies for Oncology Nurses

Release Date: December 15, 2021
Expiration Date: December 15, 2022

Activity Overview

There are now 5 FDA-approved chimeric antigen receptor (CAR) T-cell therapies (tisagenlecleucel, axicabtagene ciloleucel, brexucabtagene autoleucel, lisocabtagene maraleucel, idecabtagene vicleucel). All of these autologous agents are made from the patient’s own cells and are approved for patients with leukemia, lymphoma, or multiple myeloma in the relapsed or refractory setting. Nurses have a critical role in the multidisciplinary team that cares for patients undergoing CAR T-cell therapy, including educating patients preinfusion and monitoring patients postinfusion for adverse events, such as cytokine release syndrome, tumor lysis syndrome, or neurologic toxicities (eg, immune effector cell–associated neurotoxicity syndrome).

In this program, 2 experts in CAR T-cell therapies will present recent clinical data on CAR T-cell therapy and review the role of nurses in identifying and managing adverse events following CAR T-cell therapy.

Acknowledgement of Commercial Support

This activity is supported by an education grant from Novartis Pharmaceuticals Corporation.

Instructions for This Activity and Receiving Credit

Complete the activity (including pre- and post-activity assessments).
Answer the evaluation questions.
Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is intended for oncology nurses, nurse practitioners, and advanced practice nurses involved in the treatment of hematologic malignancies.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Summarize the role for CAR T-cell therapies across hematologic malignancies, including considerations for manufacturing and delivery to patients
Outline efficacy and safety evidence regarding current and emerging novel CAR T-cell therapies to improve outcomes in patients with hematologic malignancies
Discuss strategies to monitor and mitigate toxicities associated with CAR T-cell therapy as part of the multidisciplinary team
Employ nursing strategies to manage the personalized care plans for patients undergoing CAR T-cell therapy in the context of counseling on treatment-related toxicities and supportive care interventions

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.

Faculty

Krishna Komanduri, MD
Chief, Division of Transplantation and Cellular Therapy
Kalish Family Chair in Stem Cell Transplantation
Professor of Medicine, Microbiology, and Immunology
Sylvester Comprehensive Cancer Center
University of Miami
Miami, FL

Disclosures: Consultant: Adaptimmune, Iovance Biotherapeutics, Kite Pharma/Gilead Sciences, Novartis Pharmaceuticals Corporation, Bristol Myers Squibb, Roche, Takeda Oncology, Janssen Pharmaceuticals, Instil Bio, Avacta, Kiadis Pharma.

Juan Felipe Ramirez, APRN-BC
Senior APRN
Division of Transplantation and Cellular Therapy
University of Miami
Miami, FL

Disclosures: Juan Felipe Ramirez, APRN-BC, has no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.